Skip to main content

Sars-Cov-2 Mrna-1273 (6M-5Y) Vaccine Dosage

Applies to the following strengths: preservative-free

Usual Pediatric Dose for:

Additional dosage information:

Usual Pediatric Dose for COVID-19

For investigational use only

6 months through 5 years:

  • Primary series: 0.25 mL IM for 2 doses, administered 1 month apart

  • The US FDA issued an Emergency Use Authorization (EUA) to allow the emergency use of this unapproved product for active immunization to prevent coronavirus disease 2019 (COVID-19). This product is not approved by the US FDA for this use.
  • There are no data available regarding interchangeability of COVID-19 vaccine products; the same vaccine product should be used for both doses.
  • For additional information:

Use: Active immunization against COVID-19 due to SARS-CoV-2 (SARS-CoV-2)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available



Safety and efficacy have not been established in patients younger than 6 months.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • Administer IM.
  • Gently swirl the vial between doses; do not shake.

Storage requirements:
  • Store frozen between -50C to -15C (-58F to 5F); store in original package to protect from light.

  • Thaw each vial before use; once thawed, do not return vial to freezer.
  • Thawed vials may be handled in room light conditions.
  • Vials may be stored between 8C and 25C (46F to 77F) for a total of 24 hours.
  • Thawing vials: Consult the Fact Sheet for Health Care Providers.
  • May store vials in refrigerator between 2C to 8C (36F to 46F) for up to 30 days prior to first use.
  • In use vial (needle-punctured): Store between 2C to 25C (36F to 77F); discard vial 12 hours after first puncture.
  • Do not refreeze.

Reconstitution/preparation techniques:
  • Do not dilute.
  • Consult the Fact Sheet for Health Care Providers.

  • Each 0.25 mL dose contains 25 mcg of a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2.

Patient advice:
  • Read the Fact Sheet for Recipients and Caregivers.

More about sars-cov-2 mrna-1273 (6m-5y) vaccine

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.